

CIRM Funded Clinical Trials

Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis

Disease Area:	Osteoarthritis
Investigator:	Leonardo Sahelijo
Institution:	California Institute for Biomedical Research
CIRM Grant:	CLIN2-10388
Award Value:	\$8,447,523
Trial Sponsor:	California Institute for Biomedical Research
Trial Stage:	Phase 1
Trial Status:	Not yet recruiting
Targeted Enrollment:	60
ClinicalTrials.gov ID:	NCT03133676



Leonardo Sahelijo

Details:

Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded \$8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage in areas damaged by osteoarthritis. CIRM funded the research that developed this technology and now this Phase 1 trial will test this stem cell directed treatment in people with osteoarthritis of the knee, hopefully slowing down or even halting the progression of the disease.

Design:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study.

Goal:

This study will evaluate the safety and tolerability of KA34 when administered to patients with osteoarthritis of the knee.

[Contact Trial Sponsor](#)

Source URL: <http://www.cirm.ca.gov/clinical-trial/evaluation-safety-and-tolerability-ka34-phase-1-double-blind-dose-escalation-trial>